- Core One Labs (COOL) will host a presentation on its proprietary Biosynthetic Psilocybin Technology at an investor town hall event
- The virtual town hall event will include a presentation by Dr. Hancock on the status of Vocan’s production of biosynthetic psilocybin and a live video from the company’s operating laboratory in Victoria, British Columbia
- Core One envisions a company that addresses research and development while addressing the treatment needs of clients
- Core One is a biotechnology research and life sciences enterprise focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic-assisted psychotherapy
- Core One Labs Inc. (COOL) is up 4.07 per cent, trading at C$5.88 at 12:22 pm ET
Dr. Robert E.W. Hancock, Chairman and CEO of Core One (COOL) subsidiary Vocan Biotechnologies will be presenting at a virtual town hall meeting.
The virtual event will include a presentation by Dr. Hancock on the status of Vocan’s production of biosynthetic psilocybin and a live video from the company’s operating laboratory in Victoria, British Columbia. Dr. Hancock will also be answering questions from investors.
“Our multi-faceted business model envisions a company that addresses the full psychedelics cycle; from research in proprietary product development, developing and implementing appropriate clinical trials research, as well as addressing the treatment needs of clients in their various journeys to attaining sustained mental health well-being,” stated Joel Shacker, CEO of Core One Labs.
“I am very excited to announce that our company chairman, psychedelics as alternative medicines visionary, and world-renowned scientist, Dr. Robert Hancock will be presenting in the company’s first-ever Investors’ virtual town hall to provide all market participants with in-depth insight into some of our exciting developments,” added Shacker.
Core One is a biotechnology research and technology life sciences enterprise focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic-assisted psychotherapy.
Core One has developed a patent-pending thin film oral strip (the “technology”) which dissolves instantly when placed in the mouth and delivers organic molecules in precise quantities to the bloodstream, maintaining excellent bioavailability.
It intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. Core One also holds an interest in medical clinics which maintain a combined database of over 275,000 patients.
Through these clinics, the integration of its intellectual property, R&D related to psychedelic treatments and novel drug therapies, the company intends to obtain regulatory research approval for the advancement of psychedelic-derived treatments for mental health disorders.
Core One Labs Inc. (COOL) is up 4.07 per cent, trading at C$5.88 at 12:22 pm ET.
